Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Article

  • Article
    The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines
    Chafiq Hamdouchi, Heather Keyser, Elizabeth Collins, Carlos Jaramillo, Jose Eugenio De Diego, Charles D. Spencer, Jack Alan Dempsey, Bryan D. Anderson, Tillie Leggett, Nancy B. Stamm, Richard M. Schultz, Scott A. Watkins, Kim Cocke, Stephanie Lemke, Teresa F. Burke, Richard P. Beckmann, Jeffrey T. Dixon, Thomas M. Gurganus, Nancy B. Rankl, Keith A. Houck, Faming Zhang, Michal Vieth, Juan Espinosa, David E. Timm, Robert M. Campbell, Bharvin K. R. Patel and Harold B. Brooks
    Mol Cancer Ther January 1 2004 3 (1) 1-9;

  • Article
    Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines
    Beverly E. Barton, James G. Karras, Thomas F. Murphy, Arnold Barton and Hosea F-S. Huang
    Mol Cancer Ther January 1 2004 3 (1) 11-20;

  • Article
    Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes
    Maria Nunes, Celine Shi and Lee M. Greenberger
    Mol Cancer Ther January 1 2004 3 (1) 21-27;

  • Article
    CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer
    Tomohiko Mori, Ryuichiro Doi, Masayuki Koizumi, Eiji Toyoda, Daisuke Ito, Kazuhiro Kami, Toshihiko Masui, Koji Fujimoto, Hirokazu Tamamura, Kenichi Hiramatsu, Nobutaka Fujii and Masayuki Imamura
    Mol Cancer Ther January 1 2004 3 (1) 29-37;

  • Article
    Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid
    Takashi Ikeda, Yukiko Nakata, Fumihiko Kimura, Ken Sato, Kenneth Anderson, Kazuo Motoyoshi, Michael Sporn and Donald Kufe
    Mol Cancer Ther January 1 2004 3 (1) 39-45;

  • Article
    Biological characterization of MLN944: A potent DNA binding agent
    Darshan S. Sappal, A. Kathleen McClendon, James A. Fleming, Vala Thoroddsen, Kelly Connolly, Corinne Reimer, Ronald K. Blackman, Christine E. Bulawa, Neil Osheroff, Peter Charlton and Laura A. Rudolph-Owen
    Mol Cancer Ther January 1 2004 3 (1) 47-58;

  • Article
    The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts
    Steffan T. Nawrocki, Bridget Sweeney-Gotsch, Ryan Takamori and David J. McConkey
    Mol Cancer Ther January 1 2004 3 (1) 59-70;

  • Article
    Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis
    Ali R. Jazirehi and Benjamin Bonavida
    Mol Cancer Ther January 1 2004 3 (1) 71-84;

  • Article
    Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides
    Takashi Kurizaki, Michio Abe, Sam D. Sanderson, Charles A. Enke and Janina Baranowska-Kortylewicz
    Mol Cancer Ther January 1 2004 3 (1) 85-91;

  • Article
    Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo
    Shoichiro Ohtani, Shunsuke Kagawa, Yasuhisa Tango, Tatsuo Umeoka, Naoyuki Tokunaga, Yousuke Tsunemitsu, Jack A. Roth, Yoichi Taya, Noriaki Tanaka and Toshiyoshi Fujiwara
    Mol Cancer Ther January 1 2004 3 (1) 93-100;

Corrections

  • Corrections
    Correction
    Mol Cancer Ther January 1 2004 3 (1) 101-101;

Back to top
PreviousNext
Molecular Cancer Therapeutics: 3 (1)
January 2004
Volume 3, Issue 1
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines

Jump to

  • Article
  • Corrections
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement